TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06639256: An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Sol

Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 258 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06639256 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06639256 Rescue Dossier →